0001193125-24-113865.txt : 20240529 0001193125-24-113865.hdr.sgml : 20240529 20240425160352 ACCESSION NUMBER: 0001193125-24-113865 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Q32 Bio Inc. CENTRAL INDEX KEY: 0001661998 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473468154 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-999-0232 MAIL ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Homology Medicines, Inc. DATE OF NAME CHANGE: 20151228 CORRESP 1 filename1.htm CORRESP

Q32 Bio Inc.

830 Winter Street

Waltham, MA 02451

April 25, 2024

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance – Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

 

  Re:

Q32 Bio Inc.

Registration Statement on Form S-1

File No. 333-278829

Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Q32 Bio Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-278829) (the “Registration Statement”), so that it may become effective at 4:00 pm Eastern time on April 29, 2024, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

If you have any questions regarding this request, please contact Sarah Ashfaq of Goodwin Procter LLP at (212) 459-7238.

 

Very truly yours,

Q32 BIO INC.

By:  

/s/ Jodie Morrison

 

Name: Jodie Morrison

Title: Chief Executive Officer

cc: Sarah Ashfaq, Goodwin Procter LLP